Skip to main content
SpringerLink
Log in

Leflunomide in Combination Therapy for Rheumatoid Arthritis

  • Commentary
  • Published:
Drug Safety Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Alcorn N, Saunders S, Madhok R. Benefit-risk assessment of leflunomide: an appraisal of leflunomide in rheumatoid arthritis 10 years after licensing. Drug Saf 2009; 32(12): 1123–34

    Article  PubMed  CAS  Google Scholar 

  2. Savage RL, Highton J, Boyd IW, et al. Pneumonitis associated with leflunomide: a profile of New Zealand and Australian reports. Intern Med J 2006; 36(3): 162–9

    Article  PubMed  CAS  Google Scholar 

  3. Searles G, McKendry RJR. Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors: four case reports and a review of the literature. J Rheumatol 1987; 14: 1164–71

    PubMed  CAS  Google Scholar 

  4. Smolen JS, Graninger WB, Emery P. Leflunomide, a new disease-modifying anti-rheumatic drug and the never ending rheumatoid arthritis story [editorial]. Rheumatology 2000; 39: 689–92

    Article  PubMed  CAS  Google Scholar 

  5. Kamata Y, Nara H, Kamimura T, et al. Rheumatoid arthritis complicated with acute interstitial pneumonia induced by leflunomide as an adverse reaction. Intern Med 2004; 43(12): 1201–4

    Article  PubMed  Google Scholar 

  6. Takeishi M, Akiyama Y, Akiba H, et al. Leflunomideinduced interstitial pneumonia. J Rheumatol 2005; 32: 1160–3

    PubMed  Google Scholar 

  7. Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. Arthritis Rheum 2006; 54(5): 1435–9

    Article  PubMed  CAS  Google Scholar 

  8. Hill RL, Topliss DJ, Purcell PM. Pancytopenia associated with leflunomide and methotrexate [letter]. Ann Pharmacother 2003; 37: 149

    Article  PubMed  Google Scholar 

  9. Chan J, Sanders DC, Du L, et al. Leflunomide-associated pancytopenia with or without methotrexate. Ann Pharmacother 2004; 38(7-8): 1206–11

    Article  PubMed  Google Scholar 

  10. McEwen J, Purcell PM, Hill RL, et al. The incidence of pancytopenia in patients taking leflunomide alone or with methotrexate. Pharmacoepidemiol Drug Saf 2007; 16(1): 65–73

    Article  PubMed  CAS  Google Scholar 

  11. Weinblatt ME, Kremer JM, Coblyn JS, et al. Pharmacokinetics, safety and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42(7): 1322–8

    Article  PubMed  CAS  Google Scholar 

  12. Breedveld P, Zelcer N, Pluim D, et al. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 2004; 64: 5804–11

    Article  PubMed  CAS  Google Scholar 

  13. Kis E, Nagy T, Jani M, et al. Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance. Ann Rheum Dis 2009; 68(7): 1201–7

    Article  PubMed  CAS  Google Scholar 

  14. Jenks KA, Stamp LK, O’Donnell JL, et al. Leflunomideassociated infections in rheumatoid arthritis. J Rheumatol 2007; 34(11): 2201–3

    PubMed  CAS  Google Scholar 

  15. European Medicines Agency. EMEA public statement on leflunomide (Arava): pancytopenia and serious skin reactions [online]. Available from URL: http://www.ema.europa.eu/pdfs/human/press/pus/3163799EN.pdf [Accessed 2010 Apr 6]

  16. Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomised, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137(9): 726–33

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The author gratefully acknowledges the comments and advice provided by Dr John McEwen, Discipline of Pharmacy, University of Canberra, Canberra, ACT, Australia, and Associate Professor James Paxton, Head, Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand.

The New Zealand Pharmacovigilance Centre is funded by Medsafe, New Zealand Ministry of Health. No sources of funding were used to assist in the preparation of this commentary. The author has no actual or potential conflicts of interest.

Author information

Authors and Affiliations

  1. New Zealand Pharmacovigilance Centre, Department of Preventive and Social Medicine, University of Otago, P.O. Box 913, Dunedin, New Zealand

    Ruth L. Savage

  2. Department of Public Health and General Practice, University of Otago, Christchurch, New Zealand

    Ruth L. Savage

Authors
  1. Ruth L. Savage
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ruth L. Savage.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Savage, R.L. Leflunomide in Combination Therapy for Rheumatoid Arthritis. Drug-Safety 33, 523–526 (2010). https://doi.org/10.2165/11532390-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11532390-000000000-00000

Keywords

Search

Navigation